{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:35:07Z","timestamp":1787495707197,"version":"build-2736575974"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,6,28]],"date-time":"2015-06-28T00:00:00Z","timestamp":1435449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s40266-015-0280-y","type":"journal-article","created":{"date-parts":[[2015,6,27]],"date-time":"2015-06-27T13:02:04Z","timestamp":1435410124000},"page":"515-524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations"],"prefix":"10.1007","volume":"32","author":[{"given":"\u00c9ric","family":"Toussirot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,28]]},"reference":[{"key":"280_CR1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baten D. Spondyloarthritis. Lancet. 2011;377:2127\u201337.","journal-title":"Lancet"},{"key":"280_CR2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rdc.2012.08.002","volume":"38","author":"J Braun","year":"2012","unstructured":"Braun J, Sieper J. Classification, diagnosis, and referral of patients with axial spondyloarthritis. Rheum Dis Clin North Am. 2012;38:477\u201385.","journal-title":"Rheum Dis Clin North Am"},{"key":"280_CR3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s11926-013-0374-7","volume":"15","author":"I Olivieri","year":"2013","unstructured":"Olivieri I, D\u2019Angelo S, Padula A, et al. Spondyloarthritis with onset after age 45. Curr Rheumatol Rep. 2013;15:374.","journal-title":"Curr Rheumatol Rep."},{"key":"280_CR4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00002512-200522060-00001","volume":"22","author":"E Toussirot","year":"2005","unstructured":"Toussirot E, Wendling D. Late onset ankylosing spondylitis and related spondylarthropathies. Clinical and radiological characteristics and pharmacological treatment options. Drugs Aging. 2005;22:451\u201369.","journal-title":"Drugs Aging"},{"key":"280_CR5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"69","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Van der Heijde DM, Landew\u00e9 R, et al. The development of Assessment of Spondylarthritis international Society classification criteria for axial spondylarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;69:777\u201383.","journal-title":"Ann Rheum Dis"},{"key":"280_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde DM, Landew\u00e9 R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25\u201331.","journal-title":"Ann Rheum Dis"},{"key":"280_CR7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11926-013-0345-z","volume":"15","author":"U Weber","year":"2013","unstructured":"Weber U, Maksymowych WP. Advances and challenges in spondyloarthritis imaging for diagnosis and assessment of disease. Curr Rheumatol Rep. 2013;15:345.","journal-title":"Curr Rheumatol Rep."},{"key":"280_CR8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003495-199856020-00006","volume":"56","author":"E Toussirot","year":"1998","unstructured":"Toussirot E, Wendling D. Current guidelines for the drug treatment of ankylosing spondylitis. Drugs. 1998;56:225\u201340.","journal-title":"Drugs"},{"key":"280_CR9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrrheum.2012.40","volume":"8","author":"J Sieper","year":"2012","unstructured":"Sieper J. Developments in therapies for spondyloarthritis. Nat Rev Rheumatol. 2012;8:280\u20137.","journal-title":"Nat Rev Rheumatol"},{"key":"280_CR10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6\u201316.","journal-title":"Ann Rheum Dis"},{"key":"280_CR11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2165\/11315970-000000000-00000","volume":"27","author":"E Toussirot","year":"2010","unstructured":"Toussirot E. Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies. Drugs Aging. 2010;27:523\u201331.","journal-title":"Drugs Aging"},{"key":"280_CR12","first-page":"1214","volume":"16","author":"JJ Dubost","year":"1989","unstructured":"Dubost JJ, Sauvezie B. Late onset peripheral spondylarthropathy. J Rheumatol. 1989;16:1214\u20137.","journal-title":"J Rheumatol"},{"key":"280_CR13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/ard.56.3.176","volume":"56","author":"D Caplanne","year":"1997","unstructured":"Caplanne D, Tubach F, Le Parc JM. Late onset spondylarthropathy: clinical and biological comparison with early onset patients. Ann Rheum Dis. 1997;56:176\u20139.","journal-title":"Ann Rheum Dis"},{"key":"280_CR14","first-page":"899","volume":"22","author":"I Olivieri","year":"1995","unstructured":"Olivieri I, Padula A, Pierro A, et al. Late onset seronegative spondylarthopathy. J Rheumatol. 1995;22:899\u2013903.","journal-title":"J Rheumatol"},{"key":"280_CR15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.58.4.226","volume":"58","author":"L Punzi","year":"1999","unstructured":"Punzi L, Pianon M, Rossini P, et al. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis. 1999;58:226\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 55","key":"280_CR16","first-page":"S139","volume":"27","author":"I Olivieri","year":"2009","unstructured":"Olivieri I, Pipitone N, D\u2019Angelo S, et al. Late onset rheumatoid arthritis and late onset spondylarthritis. Clin Exp Rheumatol. 2009;27(Suppl 55):S139\u201345.","journal-title":"Clin Exp Rheumatol"},{"key":"280_CR17","first-page":"351","volume":"30","author":"TL Skare","year":"2012","unstructured":"Skare TL, Leite N, Bortoluzzo AB, et al. Effect of age at disease onset in the clinical profile of spondyloarthritis: a study of 1424 Brazilian patients. Clin Exp Rheumatol. 2012;30:351\u20137.","journal-title":"Clin Exp Rheumatol."},{"key":"280_CR18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3899\/jrheum.111082","volume":"39","author":"C Montilla","year":"2012","unstructured":"Montilla C, Del Pino-Montes J, Collantes-Estevez E, et al. Clinical features of late-onset ankylosing spondylitis: comparison with early-onset disease. J Rheumatol. 2012;39:1008\u201312.","journal-title":"J Rheumatol."},{"key":"280_CR19","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3899\/jrheum.111031","volume":"39","author":"HA Chen","year":"2012","unstructured":"Chen HA, Chen CH, Liao HT, et al. Clinical, functional, and radiographic differences among juvenile-onset, adult-onset, and late-onset ankylosing spondylitis. J Rheumatol. 2012;39:1013\u20138.","journal-title":"J Rheumatol."},{"key":"280_CR20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3899\/jrheum.080691","volume":"36","author":"FC Wilson","year":"2009","unstructured":"Wilson FC, Icen M, Crowson CS, et al. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: a population-based study. J Rheumatol. 2009;36:361\u20137.","journal-title":"J Rheumatol."},{"key":"280_CR21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/acr.20401","volume":"63","author":"L Eder","year":"2011","unstructured":"Eder L, Chandran V, Shen H, et al. Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken). 2011;63:619\u201322.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"280_CR22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361\u20138.","journal-title":"Arthritis Rheum"},{"key":"280_CR23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/ard.2006.054288","volume":"66","author":"PS Helliwell","year":"2007","unstructured":"Helliwell PS, Porter G, Taylor WJ, CASPAR Study Group. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Ann Rheum Dis. 2007;66:113\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"280_CR24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2013-eular.2027","volume":"72","author":"S D\u2019Angelo","year":"2013","unstructured":"D\u2019Angelo S, Gilio M, Palazzi C, et al. Clinical and laboratory features of late-onset psoriatic arthritis in comparison with younger-onset disease: data from an early arthritis cohort. Ann Rheum Dis. 2013;72(Suppl 3):686.","journal-title":"Ann Rheum Dis"},{"key":"280_CR25","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1002\/art.27571","volume":"62","author":"U Weber","year":"2010","unstructured":"Weber U, Lambert RG, \u00d8stergaard M, et al. The diagnostic utility of magnetic resonance imaging in spondylarthritis: an international multicenter evaluation of one hundred eighty-seven subjects. Arthritis Rheum. 2010;62:3048\u201358.","journal-title":"Arthritis Rheum."},{"key":"280_CR26","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/art.24493","volume":"60","author":"AN Bennett","year":"2009","unstructured":"Bennett AN, Rehman A, Hensor EM, et al. Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis. Arthritis Rheum. 2009;60:1331\u201341.","journal-title":"Arthritis Rheum"},{"key":"280_CR27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/art.24507","volume":"61","author":"U Weber","year":"2009","unstructured":"Weber U, Hodler J, Kubik RA, et al. Sensitivity and specificity of spinal inflammatory lesions assessed by whole-body magnetic resonance imaging in patients with ankylosing spondylitis or recent onset inflammatory back pain. Arthritis Rheum. 2009;61:900\u20138.","journal-title":"Arthritis Rheum"},{"key":"280_CR28","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging for classification of axial spondylarthritis: a consensual approach by ASAS\/OMERACT MRI group. Ann Rheum Dis. 2009;68:1520\u20137.","journal-title":"Ann Rheum Dis"},{"key":"280_CR29","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/ard.2011.150680","volume":"71","author":"KG Hermann","year":"2012","unstructured":"Hermann KG, Baraliakos X, van der Heijde DM, et al. Assessment in SpondyloArthritis international Society (ASAS). Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI study group. Ann Rheum Dis. 2012;71:1278\u201388.","journal-title":"Ann Rheum Dis."},{"key":"280_CR30","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1136\/ard.2007.069542","volume":"66","author":"S Shankaranarayana","year":"2007","unstructured":"Shankaranarayana S, Tan AL, Madden J, et al. Fat-suppression magnetic resonance imaging in the diagnosis of late-onset axial spondyloarthropathy. Ann Rheum Dis. 2007;66:1405\u20136.","journal-title":"Ann Rheum Dis."},{"key":"280_CR31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s776-002-8407-1","volume":"7","author":"Y Shibata","year":"2002","unstructured":"Shibata Y, Shirai Y, Miyamoto M. The aging process in the sacroiliac joint: helical computed tomography analysis. J Orthop Sci. 2002;7:12\u20138.","journal-title":"J Orthop Sci."},{"key":"280_CR32","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1016\/j.ejrad.2012.03.033","volume":"8","author":"J Herrmann","year":"2012","unstructured":"Herrmann J, Krstin N, Schoennagel BP, et al. Age-related distribution of vertebral bone-marrow diffusivity. Eur J Radiol. 2012;8:4046\u20139.","journal-title":"Eur J Radiol."},{"key":"280_CR33","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1136\/ard.2010.138701","volume":"70","author":"MA D\u2019Agostino","year":"2011","unstructured":"D\u2019Agostino MA, Aegerter P, Bechara K, et al. How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography. Ann Rheum Dis. 2011;70:1433\u201340.","journal-title":"Ann Rheum Dis."},{"key":"280_CR34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landew\u00e9 R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492\u2013509.","journal-title":"Ann Rheum Dis."},{"key":"280_CR35","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YP Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381\u201390.","journal-title":"Arthritis Rheum."},{"key":"280_CR36","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/annrheumdis-2013-203860","volume":"73","author":"MM Schoels","year":"2014","unstructured":"Schoels MM, Braun J, Dougados M, et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis. 2014;73:238\u201342.","journal-title":"Ann Rheum Dis."},{"key":"280_CR37","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, Van Der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44:1876\u201386.","journal-title":"Arthritis Rheum"},{"key":"280_CR38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, Landew\u00e9 R, Sieper J, et al. Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18\u201324.","journal-title":"Ann Rheum Dis."},{"key":"280_CR39","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","volume":"72","author":"PS Helliwell","year":"2013","unstructured":"Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986\u201391.","journal-title":"Ann Rheum Dis."},{"key":"280_CR40","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387\u201394.","journal-title":"Ann Rheum Dis."},{"key":"280_CR41","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2474-14-101","volume":"14","author":"LC Coates","year":"2013","unstructured":"Coates LC, Navarro-Coy N, Brown SR, et al. The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskelet Disord. 2013;14:101.","journal-title":"BMC Musculoskelet Disord."},{"issue":"suppl","key":"280_CR42","first-page":"S346","volume":"65","author":"LC Coates","year":"2013","unstructured":"Coates LC, Moverley A, McPArland L, et al. Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control imorve outcome. Arthritis Rheum. 2013;65(suppl):S346.","journal-title":"Arthritis Rheum"},{"key":"280_CR43","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet. 2002;359:1187\u201393.","journal-title":"Lancet"},{"key":"280_CR44","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis","year":"2003","unstructured":"Davis JC, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. A randomized, controlled trial. Arthritis Rheum. 2003;48:3230\u20136.","journal-title":"Arthritis Rheum"},{"key":"280_CR45","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"Van Heijde der","year":"2006","unstructured":"der Heijde Van, Kivitz A, Schiff M, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136\u201346.","journal-title":"Arthritis Rheum"},{"key":"280_CR46","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis JC, Van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis. Results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402\u201312.","journal-title":"Arthritis Rheum"},{"key":"280_CR47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landewe","year":"2014","unstructured":"Landewe R, Barun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double blind randomised placebo controlled phase 3 study. Ann Rheum Dis. 2014;73:39\u201347.","journal-title":"Ann Rheum Dis."},{"key":"280_CR48","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2012-201766","volume":"72","author":"J Sieper","year":"2013","unstructured":"Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non \u2013radiographic axial spondyloarthritis: results of a randomized placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815\u201322.","journal-title":"Ann Rheum Dis."},{"key":"280_CR49","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","volume":"66","author":"M Dougados","year":"2014","unstructured":"Dougados M, Van der Heijde D, Sieper J, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiogarphic axial spondyloarthritis. A multicentre, randomised, double blind, placebo controlled trial. Arthritis Rheumatol. 2014;66:2091\u2013102.","journal-title":"Arthritis Rheumatol."},{"key":"280_CR50","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385\u201390.","journal-title":"Lancet"},{"key":"280_CR51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"C Antoni","year":"2005","unstructured":"Antoni C, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227\u201336.","journal-title":"Arthritis Rheum"},{"key":"280_CR52","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","volume":"56","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476\u201388.","journal-title":"Arthritis Rheum"},{"key":"280_CR53","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","volume":"64","author":"A Kavanaugh","year":"2012","unstructured":"Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64:2504\u201317.","journal-title":"Arthritis Rheum."},{"key":"280_CR54","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48\u201355.","journal-title":"Ann Rheum Dis."},{"key":"280_CR55","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/rheumatology\/kes026","volume":"51","author":"X Baraliakos","year":"2012","unstructured":"Baraliakos X, van den Berg R, Braun J, et al. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS\/EULAR management recommendations of ankylosing spondylitis. Rheumatology. 2012;51:1378\u201387.","journal-title":"Rheumatology"},{"key":"280_CR56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71:4\u201312.","journal-title":"Ann Rheum Dis."},{"key":"280_CR57","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jbspin.2014.10.012","volume":"82","author":"C Lahaye","year":"2015","unstructured":"Lahaye C, Tatar Z, Dubost JJ, et al. Overview of biologic treatments in the elderly. Jt Bone Spine. 2015;82:154\u201360.","journal-title":"Jt Bone Spine"},{"key":"280_CR58","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2165\/11316460-000000000-00000","volume":"26","author":"BJ Radovits","year":"2009","unstructured":"Radovits BJ, Kievit W. Laan RFJM. Tumour necrosis factor \u03b1 antagonists in the management of rheumatoid arthritis in the elderly. A review of their efficacy and safety. Drugs Aging. 2009;26:647\u201364.","journal-title":"Drugs Aging"},{"key":"280_CR59","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/ard.2005.051144","volume":"65","author":"Z Tutuncu","year":"2006","unstructured":"Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65:1226\u20139.","journal-title":"Ann Rheum Dis."},{"key":"280_CR60","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/acr.20550","volume":"63","author":"VK Kawai","year":"2011","unstructured":"Kawai VK, Grijalva CG, Arbogast PG, et al. Changes in cotherapies after initiation of disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63:1415\u201324.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"280_CR61","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/ard.2005.035287","volume":"65","author":"R Fleischmann","year":"2006","unstructured":"Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65:379\u201384.","journal-title":"Ann Rheum Dis"},{"key":"280_CR62","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2165\/00002512-200724030-00005","volume":"24","author":"R Fleischmann","year":"2007","unstructured":"Fleischmann R, Iqbal I. Risk\/benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging. 2007;24:239\u201354.","journal-title":"Drugs Aging"},{"key":"280_CR63","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","volume":"56","author":"S Schneeweiss","year":"2007","unstructured":"Schneeweiss S, Setoguchi S, Weinblatt L, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:1754\u201364.","journal-title":"Arthritis Rheum"},{"key":"280_CR64","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/art.22688","volume":"57","author":"S Genevay","year":"2007","unstructured":"Genevay S, Finchk A, Ciurea A, et al. Tolerance and effectiveness of anti-tumor necrosis factor a therapies in elderly patients with rheumatoid arthritis: a population based cohort study. Arthritis Rheum. 2007;57:679\u201385.","journal-title":"Arthritis Rheum"},{"key":"280_CR65","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/ard.2008.094730","volume":"68","author":"BJ Radovits","year":"2009","unstructured":"Radovits BJ, Kievit W, Fransen J, et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1470\u20133.","journal-title":"Ann Rheum Dis"},{"key":"280_CR66","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-009-8142-1","volume":"38","author":"M Fillipini","year":"2010","unstructured":"Fillipini M, Bazzani C, Favalli EG, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010;38:90\u20136.","journal-title":"Clin Rev Allergy Immunol"},{"key":"280_CR67","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2165\/00002512-200623110-00001","volume":"23","author":"P Ornetti","year":"2006","unstructured":"Ornetti P, Chevillotte H, Zerrak A, et al. Anti-tumour necrosis factor-alpha therapy for rheumatoid arthritis and other inflammatory arthropathies: update on safety in older patients. Drugs Aging. 2006;23:855\u201360.","journal-title":"Drugs Aging"},{"key":"280_CR68","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2165\/11316350-000000000-00000","volume":"26","author":"S Tran","year":"2009","unstructured":"Tran S, Hooker RS, Cipher DJ, et al. Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post marketing study. Drugs Aging. 2009;26:607\u201315.","journal-title":"Drugs Aging"},{"key":"280_CR69","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/039463200902200218","volume":"22","author":"A Migliore","year":"2009","unstructured":"Migliore A, Bizzi E, Lagana B, et al. The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol. 2009;22:415\u201326.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"280_CR70","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/keh562","volume":"44","author":"H Chevillotte-Maillard","year":"2005","unstructured":"Chevillotte-Maillard H, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. Rheumatology. 2005;44:695\u20136.","journal-title":"Rheumatology"},{"key":"280_CR71","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152812800392805","volume":"11","author":"E Toussirot","year":"2012","unstructured":"Toussirot E. The IL23\/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets. 2012;11:159\u201368.","journal-title":"Inflamm Allergy Drug Targets"},{"key":"280_CR72","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73:990\u20139.","journal-title":"Ann Rheum Dis."},{"key":"280_CR73","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705\u201313.","journal-title":"Lancet"},{"key":"280_CR74","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020\u20136.","journal-title":"Ann Rheum Dis."},{"key":"280_CR75","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00002512-200926040-00001","volume":"26","author":"A Diaz-Borjon","year":"2009","unstructured":"Diaz-Borjon A. Guidelines for the use of conventional and newer disease modifying antirheumatic drugs in elderly patients with rheumatoid arthritis. Drugs Aging. 2009;26:273\u201393.","journal-title":"Drugs Aging"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0280-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-015-0280-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0280-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T15:35:02Z","timestamp":1566920102000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-015-0280-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,28]]},"references-count":75,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["280"],"URL":"https:\/\/doi.org\/10.1007\/s40266-015-0280-y","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,28]]}}}